2 results
Approved WMOCompleted
Primary objective1. To demonstrate the efficacy of at least one of three doses of ACT-128800 as compared to placebo in patients withrelapsing-remitting multiple sclerosis (RRMS) on the cumulative number of new gadolinium-enhancing lesionsper patient…
Approved WMOPending
Primary:- To evaluate the safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab- Part 3 Neoadjuvant Cohorts (Cohorts 3c and 3d…